[][com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=80616]], camposKey:2227-9059 2023-10-01 Prognostic Significance of Amino Acid and Biogenic Amines Profiling in Chronic Kidney Disease00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=78277]], camposKey:2254-4070 2023-01-01 Análisis del rendimiento físico durante un torneo corto en jugadores de baloncesto semiprofesionales00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=74346]], camposKey:1474-0338 2023-01-01 Hydroxychloroquine safety in Covid-19 vs non-Covid-19 patients: analysis of differences and potential interactions7179, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=74343]], camposKey:1549-1684 2022-07-08 Physical Condition and Risk of Hospitalization and Polypharmacy in Older Adults00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=74347]], camposKey:2077-0383 2022-05-01 Effects of Antioxidants on Pain Perception in Patients with Fibromyalgia¿A Systematic Review00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=74348]], camposKey:2072-6643 2022-01-01 Haplotypes in the GC, CYP2R1 and CYP24A1 Genes and Biomarkers of Bone Mineral Metabolism in Older Adults00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=74349]], camposKey:2077-0383 2021-06-01 Does the addition of pain neurophysiology education to a therapeutic exercise program improve physical function in women with fibromyalgia syndrome? Secondary analysis of a randomized controlled trial00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=65943]], camposKey:1661-7827 2021-02-01 Muscular strength and quality of life in older adults: The role of ACTN3 R577X polymorphism110, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=74350]], camposKey:2077-0383 2020-11-01 Therapeutic exercise and pain neurophysiology education in female patients with fibromyalgia syndrome: A feasibility study115, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=66756]], camposKey:0300-2896 2020-10-01 Hydroxychloroquine and Potential Drug Interactions in Older Adults679681, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=58197]], camposKey:1661-7827 2020-01-01 Mishel¿s model of uncertainty describing categories and subcategories in fibromyalgia patients, a scoping review00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=52453]], camposKey:0300-2896 2019-01-01 Association of HTR2A-1438G/A Genetic Polymorphism With Smoking and Chronic Obstructive Pulmonary Disease Asociación del polimorfismo genético HTR2A-1438G/A con el tabaco y la enfermedad pulmonar obstructiva crónica128133, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=52456]], camposKey:2072-6643 2019-01-01 Bone mineral metabolism status, quality of life, and muscle strength in older people00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=52454]], camposKey:0300-2896 2019-01-01 New Biomarkers for Smoking: Epigenetic Changes Nuevos biomarcadores en tabaquismo: modificaciones epigenéticas293294, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=52451]], camposKey:1661-7827 2019-01-01 Physical performance and quality of life in older adults: Is there any association between them and potential drug interactions in polymedicated octogenarians00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=52460]], camposKey:0531-5565 2019-01-01 Physical performance, plasma S-klotho, and all-cause mortality in elderly dialysis patients: A prospective cohort study123128, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=74345]], camposKey:0268-1161 2017-07-01 Two LH beta-subunit polymorphisms are equally correlated with ovarian response in oocyte donors289289, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=8917]], camposKey:0341-2040 2017-01-01 A Paradox: alpha-Klotho Levels and Smoking Intensity5357, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=8921]], camposKey:0195-9131 2017-01-01 Exercise Intervention in Pediatric Patients with Solid Tumors: The Physical Activity in Pediatric Cancer Trial223230, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=8916]], camposKey:1555-0265 2017-01-01 Telomere Length in Elite Athletes994996, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=52455]], camposKey:1661-6596 2016-01-01 Effect of genetic polymorphisms and long-term tobacco exposure on the risk of breast cancer00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=51923]], camposKey:1462-2203 2016-01-01 The Effect of Polymorphisms in DNA Repair Genes and Carcinogen Metabolizers on Leukocyte Telomere Length: A Cohort of Healthy Spanish Smokers447452, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=8918]], camposKey:1932-6203 2015-01-01 Are SNP-Smoking Association Studies Needed in Controls? DNA Repair Gene Polymorphisms and Smoking Intensity00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=8919]], camposKey:0013-9351 2015-01-01 Effects of cigarette smoking and nicotine metabolite ratio on leukocyte telomere length.488494, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=8935]], camposKey:1663-4365 2015-01-01 Exceptional longevity and muscle and fitness related genotypes: a functional in vitro analysis and case-control association replication study with SNPs THRH rs7832552, IL6 rs1800795, and ACSL1 rs655282800, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=43605]], camposKey:1885-3137 2015-01-01 Genetic variants in the PPARD-PPARGC1A-NRF-TFAM mitochondriogenesis pathway are neither associated with muscle characteristics nor physical performance in elderly.196208, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=8924]], camposKey:0899-8493 2015-01-01 Physical-Capacity-Related Genetic Polymorphisms in Children with Cystic Fibrosis102112, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=8931]], camposKey:1555-0265 2014-01-01 ACTN3 R577X Polymorphism and Explosive Leg-Muscle Power in Elite Basketball Players226232, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=8937]], camposKey:0531-5565 2014-01-01 ApoE gene and exceptional longevity: Insights from three independent cohorts1623, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=8925]], camposKey:0176-3679 2014-01-01 Are Serotonergic System Genes Associated to Smoking Cessation Therapy Success in Addition to CYP2A6?330, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=51924]], camposKey:0025-7753 2013-01-01 Genetics of the tobacco smoking6667, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=8929]], camposKey:1932-6203 2012-01-01 Acyl Coenzyme A Synthetase Long-Chain 1 (ACSL1) Gene Polymorphism (rs6552828) and Elite Endurance Athletic Status: A Replication Study00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=8936]], camposKey:0905-7188 2011-01-01 ACTN3 R577X polymorphism does not influence explosive leg muscle power in elite volleyball players00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=8920]], camposKey:1073-449X 2011-01-01 Cardiovascular Biological Risk Markers In Patients With COPD00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=8923]], camposKey:1073-449X 2011-01-01 Metylene Tetrahydrofolate Reductase (MTHFR) C677T Gene Polymorphisms In Patients With COPD00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=8927]], camposKey:1932-6203 2011-01-01 'Smoking Genes': A Genetic Association Study00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=8928]], camposKey:1932-6203 2010-01-01 A Novel, Single Algorithm Approach to Predict Acenocoumarol Dose Based on CYP2C9 and VKORC1 Allele Variants00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=8930]], camposKey:0172-4622 2010-01-01 ACE and ACTN3 Genes and Muscle Phenotypes in Nonagenarians221224, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=8938]], camposKey:1094-8341 2010-01-01 Are elite endurance athletes genetically predisposed to lower disease risk?8290, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=8934]], camposKey:0905-7188 2010-01-01 Is there an association between ACTN3 R577X polymorphism and muscle power phenotypes in young, non-athletic adults?771778, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=8932]], camposKey:0172-4622 2009-01-01 Genotype Distributions in Top-level Soccer Players: A Role for ACE?387392, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=8926]], camposKey:0022-3751 2009-01-01 Is there an optimum endurance polygenic profile ?15271534, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=8933]], camposKey:0340-6245 2009-01-01 Pharmacogenetics of acenocoumarol: CYP2C9*2 and VKORCI c.-1639G > A, 497C > G, 1173C > T and 3730G > A variants influence drug dose in anticoagulated patients591593, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=8922]], camposKey:0306-3674 2009-01-01 Unique among unique. Is it genetically determined?307309][CapitolsLlib{id=com.sigma.fs3.argos.domain.gpc.GpcCapitolsLlibPK[ifcactivitat=CAP, ifccomptador=30294]},camposKey: 143 152 Ancianos, medicación y riesgos asociados: datos del Sistema Español de Farmacovigilancia (SEFV-H) 978-84-09-48787-5Adaptación a nuevas demandas para la actualización de competencias en salud a lo largo del ciclo vital 1 2023-01-01 Asociación Universitaria de Educación y Psicología (ASUNIVEP) , CapitolsLlib{id=com.sigma.fs3.argos.domain.gpc.GpcCapitolsLlibPK[ifcactivitat=CAP, ifccomptador=30295]},camposKey: 225 234 Implicación de la senescencia vascular en las principales causas de muertede los países de altos ingresos 978-84-09-48787-5Adaptación a nuevas demandas para la actualización de competencias en salud a lo largo del ciclo vital 1 2023-01-01 Asociación Universitaria de Educación y Psicología (ASUNIVEP) , CapitolsLlib{id=com.sigma.fs3.argos.domain.gpc.GpcCapitolsLlibPK[ifcactivitat=CAP, ifccomptador=30296]},camposKey: 181 186 Relación del estado funcional, calidad de vida autopercibida y otros parámetros, con el riesgo clínico de personas mayores 978-84-09-48787-5Adaptación a nuevas demandas para la actualización de competencias en salud a lo largo del ciclo vital 1 2023-01-01 Asociación Universitaria de Educación y Psicología (ASUNIVEP) , CapitolsLlib{id=com.sigma.fs3.argos.domain.gpc.GpcCapitolsLlibPK[ifcactivitat=CAP, ifccomptador=22824]},camposKey: 1202 1213 Satisfacción, motivación y aprendizaje de los estudiantes de enfermería en prácticas farmacológicas con metodología flipped classroom 978-84-18348-11-2La docencia en la Enseñanza Superior: Nuevas aportaciones desde la investigación e innovación educativas 1 2020-01-01 Octaedro , CapitolsLlib{id=com.sigma.fs3.argos.domain.gpc.GpcCapitolsLlibPK[ifcactivitat=CAP, ifccomptador=18899]},camposKey: 109 112 Estudio Up and Down: prevalencia de polimorfismos genéticos en ECA, FTO y PPARGC1A 84-697-1248-9VIII Congreso Internacional de la Asociación Española de Ciencias del Deporte: Libro de actas, Cáceres, 13, 14 y 15 de Noviembre del 2014 1 2014-01-01 Asociación Española de Ciencias del Deporte, CapitolsLlib{id=com.sigma.fs3.argos.domain.gpc.GpcCapitolsLlibPK[ifcactivitat=CAP, ifccomptador=18902]},camposKey: 386 393 Modelo de adaptación de la asignatura experimental Taller de Criminalística II al modelo de estudios online 978-84-95433-66-4Educar para transformar: XI Jornadas Internacionales de Innovación Universitaria 1 2014-01-01 Universidad Europea de Madrid][][][com.sigma.fs3.argos.domain.gpc.AltresActivPers[id=com.sigma.fs3.argos.domain.gpc.GpcAltresActivPersPK[ifcactivitat=AAP, ifccomptador=972]]][][][com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBeca[id=com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBecaPK[ifcactivitat=AAB, ifccomptador=64580]], com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBeca[id=com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBecaPK[ifcactivitat=AAB, ifccomptador=64483]]][com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBeca[id=com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBecaPK[ifcactivitat=AAB, ifccomptador=64580]], com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBeca[id=com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBecaPK[ifcactivitat=AAB, ifccomptador=64483]]][][][][][][][][][][][com.sigma.investigacion.cawdos.utilidades.CongresoYSusAsociaciones@7ac390f2][][com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@5d3e62, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@5d3df9, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@5d3df7, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@5d3d54, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@5d3df4, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@5d3df3][][][com.sigma.fs3.argos.domain.gpc.EstadesFora[id=com.sigma.fs3.argos.domain.gpc.GpcEstadesForaPK[ifcactivitat=ESF, ifccomptador=61786]], com.sigma.fs3.argos.domain.gpc.EstadesFora[id=com.sigma.fs3.argos.domain.gpc.GpcEstadesForaPK[ifcactivitat=ESF, ifccomptador=61575]], com.sigma.fs3.argos.domain.gpc.EstadesFora[id=com.sigma.fs3.argos.domain.gpc.GpcEstadesForaPK[ifcactivitat=ESF, ifccomptador=60580]]][com.sigma.fs3.argos.domain.gpc.EstadesFora[id=com.sigma.fs3.argos.domain.gpc.GpcEstadesForaPK[ifcactivitat=ESF, ifccomptador=61786]], com.sigma.fs3.argos.domain.gpc.EstadesFora[id=com.sigma.fs3.argos.domain.gpc.GpcEstadesForaPK[ifcactivitat=ESF, ifccomptador=61575]], com.sigma.fs3.argos.domain.gpc.EstadesFora[id=com.sigma.fs3.argos.domain.gpc.GpcEstadesForaPK[ifcactivitat=ESF, ifccomptador=60580]]][][][][com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@5bb54c], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@5702c3], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@5ba0a0], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@5bbae2], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@4650ed], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@5ba099], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@414ec8], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@5ba09d], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@5ba09a], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@5ba09f], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@5ba09b]][][CatedrasConvenios{id=19, codigoPersona=com.sigma.fs3.argos.domain.gpc.PersonalGPC[ifcidPers=28876], codigoTipo=CAT, codigoContable=null, titulo=CATEDRA AGENDA URBANA ESPAÑOLA 2030 PARA EL DESARROLLO LOCAL, fechaInicio=2021-05-17, fechaFin=null, importe=135000.0, visiblePortal=1, visibleCvn=1, visibleMemoria=1, validado=S}][][][][com.sigma.fs3.argos.domain.gpc.altres.ProjecteInnovacio@15ac0, com.sigma.fs3.argos.domain.gpc.altres.ProjecteInnovacio@15b97][]
